- Home
- LUNG vs MGNX Comparison
LUNG vs MGNX Comparison
Compare LUNG & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- MGNX
- Stock Information
- Founded
- LUNG 1995
- MGNX 2000
- Country
- LUNG United States
- MGNX United States
- Employees
- LUNG N/A
- MGNX N/A
- Industry
- LUNG Industrial Specialties
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- MGNX Health Care
- Exchange
- LUNG Nasdaq
- MGNX Nasdaq
- Market Cap
- LUNG 251.5M
- MGNX 257.3M
- IPO Year
- LUNG 2020
- MGNX 2013
- Fundamental
- Price
- LUNG $6.23
- MGNX $3.17
- Analyst Decision
- LUNG Buy
- MGNX Hold
- Analyst Count
- LUNG 6
- MGNX 10
- Target Price
- LUNG $11.92
- MGNX $7.17
- AVG Volume (30 Days)
- LUNG 252.9K
- MGNX 506.1K
- Earning Date
- LUNG 02-19-2025
- MGNX 11-05-2024
- Dividend Yield
- LUNG N/A
- MGNX N/A
- EPS Growth
- LUNG N/A
- MGNX N/A
- EPS
- LUNG N/A
- MGNX N/A
- Revenue
- LUNG $79,302,000.00
- MGNX $141,329,000.00
- Revenue This Year
- LUNG $22.26
- MGNX $174.73
- Revenue Next Year
- LUNG $18.72
- MGNX N/A
- P/E Ratio
- LUNG N/A
- MGNX N/A
- Revenue Growth
- LUNG 22.34
- MGNX 16.68
- 52 Week Low
- LUNG $5.46
- MGNX $2.95
- 52 Week High
- LUNG $14.84
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- LUNG 41.37
- MGNX 41.22
- Support Level
- LUNG $5.72
- MGNX $3.10
- Resistance Level
- LUNG $6.28
- MGNX $3.45
- Average True Range (ATR)
- LUNG 0.40
- MGNX 0.20
- MACD
- LUNG -0.03
- MGNX -0.01
- Stochastic Oscillator
- LUNG 19.85
- MGNX 17.24
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).